Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Equivalents (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Cash & Equivalents for 4 consecutive years, with $37.9 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Cash & Equivalents fell 39.83% year-over-year to $37.9 million, compared with a TTM value of $37.9 million through Sep 2023, down 39.83%, and an annual FY2022 reading of $23.0 million, down 51.72% over the prior year.
  • Cash & Equivalents was $37.9 million for Q3 2023 at Terns Pharmaceuticals, down from $80.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $169.4 million in Q1 2023 and bottomed at $11.7 million in Q1 2020.
  • Average Cash & Equivalents over 4 years is $55.6 million, with a median of $47.7 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents surged 744.98% in 2021, then crashed 75.14% in 2022.
  • Year by year, Cash & Equivalents stood at $74.9 million in 2020, then crashed by 36.28% to $47.7 million in 2021, then crashed by 51.72% to $23.0 million in 2022, then skyrocketed by 64.54% to $37.9 million in 2023.
  • Business Quant data shows Cash & Equivalents for TERN at $37.9 million in Q3 2023, $80.9 million in Q2 2023, and $169.4 million in Q1 2023.